Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

373
The pathophysiology of pneumonia involves the following steps:
373
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

295
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
295
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

289
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
289
Pneumonia IV: Management01:28

Pneumonia IV: Management

405
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
405
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.3K
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

22
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026
Same author

Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study.

Polish archives of internal medicine·2026
Same author

Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.

Frontiers in medicine·2026
Same author

Cladribine treatment of a young patient with isolated progressive pulmonary Langerhans histiocytosis complicated by invasive aspergillosis.

Polish archives of internal medicine·2026
Same author

Access to lymphangioleiomyomatosis care across Europe: an ERN-LUNG survey of clinical practice, and the case for a European registry and trial network.

ERJ open research·2026
Same author

High prevalence of TSC2 mutations in lung tissue samples from patients with sporadic lymphangioleiomyomatosis.

The European respiratory journal·2026

Related Experiment Video

Updated: Jul 31, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.2K

Update on cryptogenic organizing pneumonia.

Elzbieta Radzikowska1, Justyna Fijolek1

  • 1III Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.

Frontiers in Medicine
|May 8, 2023
PubMed
Summary

Cryptogenic organizing pneumonia (COP) is an idiopathic lung disease. While typically mild and responsive to steroids, some forms require advanced therapies.

Keywords:
acute fibrinous organizing pneumoniacicatrices organizing pneumoniaclarithromycincryptogenic organizing pneumoniaprednisonesecondary organizing pneumonia

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

485
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.1K

Related Experiment Videos

Last Updated: Jul 31, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.2K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

485
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.1K

Area of Science:

  • Pulmonology
  • Pathology

Background:

  • Cryptogenic organizing pneumonia (COP) is an idiopathic interstitial pneumonia.
  • Secondary organizing pneumonia (OP) is linked to identified factors like infections, toxins, drugs, and autoimmune diseases.
  • Drug-induced OP is increasingly reported, with new therapies like biologicals, interferon, monoclonal antibodies, and PD1/PDL-1 inhibitors potentially triggering this lung reaction.

Purpose of the Study:

  • To review the characteristics of cryptogenic organizing pneumonia (COP).
  • To highlight the increasing incidence of drug-induced organizing pneumonia (OP).
  • To discuss the therapeutic implications of different OP forms in the context of steroid-sparing treatments.

Main Methods:

  • Literature review of cryptogenic organizing pneumonia (COP) and drug-induced organizing pneumonia (OP).
  • Analysis of clinical and histological features of various OP forms.
  • Discussion of treatment strategies, including steroid-based and steroid-sparing therapies.

Main Results:

  • Classical COP is usually subacute, with preserved respiratory function, and responds well to steroids.
  • Specific OP forms, such as cicatricial or acute fibrinous types, present distinct features and a poorer prognosis, necessitating higher immunosuppressive drug doses.
  • Newer therapies are associated with an increased risk of drug-induced OP.

Conclusions:

  • COP is a significant idiopathic interstitial pneumonia.
  • Drug-induced OP is an emerging concern, particularly with novel therapeutic agents.
  • Tailored treatment approaches, considering steroid-sparing options, are crucial for managing different forms of OP.